While knocking out/blocking FGL2 has subtle effects on altering immune cell phenotypes in the TME, resulting in prolonged survival in only some models of cancer, the results of this study show that it can potently synergize with oncolytic virus immunotherapy to successfully prolong survival in a model that is primed by the absence of FGL2. Here, FGL2 is linked to cancer.